Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Heeg · SciRah

Researcher profile · Semantic Scholar

B. Heeg

Share profile

B. Heeg — researcher profile on SciRah

h-index: 18
Works: 233
Citations: 1,296

Most-cited papers

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
N. Munshi, H. Avet-Loiseau, K. Anderson, P. Neri +12 more
2020Blood Advances381 citations Open access
Semantic Scholar
MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
J. Mazières, H. Vioix, B. Pfeiffer, R. Campden +3 more
2023Clinical Lung Cancer73 citations Open access
Semantic Scholar
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.
I. van Oostrum, M. Ouwens, Antonio Remiro-Azócar, G. Baio +3 more
2021Value in Health33 citations Open access
Semantic Scholar
Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions.
F. Soikkeli, M. Hashim, M. Ouwens, M. Postma +1 more
2019Value in Health26 citations Open access
Semantic Scholar
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
M. Rozenbaum, Andrea Garcia, D. Grima, D. Tran +6 more
2021European Heart Journal - Quality of Care and Clinical Outcomes25 citations Open access
Semantic Scholar
Network meta‐interpolation: Effect modification adjustment in network meta‐analysis using subgroup analyses
Ofir Harari, M. Soltanifar, J. Cappelleri, A. Verhoek +3 more
2022Research Synthesis Methods19 citations Open access
Semantic Scholar
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
J. Cortes, B. Muresan, C. Mamolo, J. Cappelleri +5 more
2019Current Medical Research and Opinion17 citations
Semantic Scholar
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study
S. Stintzing, I. van Oostrum, C. Pescott, P. Ronga +2 more
2020Journal of Medical Economics15 citations Open access
Semantic Scholar
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
A. Verhoek, P. Cheema, B. Melosky, B. Samson +10 more
2023PharmacoEconomics - Open14 citations Open access
Semantic Scholar
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
M. Mateos, J. San-Miguel, H. Goldschmidt, P. Sonneveld +7 more
2020Leukemia and Lymphoma13 citations
Semantic Scholar
Novel and existing flexible survival methods for network meta-analyses.
B. Heeg, Andrea Garcia, S. Beekhuizen, A. Verhoek +5 more
2022Journal of Comparative Effectiveness Research9 citations Open access
Semantic Scholar
A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients.
U. Sbarigia, T. Vincken, P. Wigfield, M. Hashim +2 more
2020Journal of Comparative Effectiveness Research8 citations Open access
Semantic Scholar
Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.
T. Russell-Smith, L. Gurskyte, B. Muresan, C. Mamolo +3 more
2022Future Oncology7 citations Open access
Semantic Scholar
Bridging the gap between oncology clinical trials and real-world data: evidence on replicability of efficacy results using German claims data.
M. Ghiani, U. Maywald, T. Wilke, B. Heeg
2022Journal of Comparative Effectiveness Research6 citations
Semantic Scholar
Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
B. Muresan, C. Mamolo, J. Cappelleri, M. Postma +1 more
2021Applied Health Economics and Health Policy6 citations Open access
Semantic Scholar
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
B. Muresan, C. Mamolo, J. Cappelleri, E. Leip +2 more
2021Current Medical Research and Opinion6 citations Open access
Semantic Scholar
The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Sophie van Beekhuizen, Yannan Hu, A. Gezin, B. Heeg +5 more
20206 citations
Semantic Scholar
The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations
S. Gebregergish, M. Hashim, B. Heeg, T. Wilke +2 more
2020Expert review of pharmacoeconomics & outcomes research6 citations
Semantic Scholar
Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant Data.
M. Aly, M. Hashim, B. Heeg, J. Liwing +5 more
2019European Urology Focus6 citations Open access
Semantic Scholar
The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada
Yannan Hu, M. Charaan, I. van Oostrum, B. Heeg +1 more
2021Journal of Medical Economics5 citations Open access
Semantic Scholar
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
V. Hungria, D. Martínez-Baños, M. Mateos, M. Dimopoulos +7 more
2020Advances in Therapy5 citations Open access
Semantic Scholar
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)
M. Dimopoulos, M. Cavo, M. Mateos, T. Facon +7 more
2019Leukemia and Lymphoma5 citations
Semantic Scholar
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Jian-Ming He, Heather Berringer, B. Heeg, Haoyao Ruan +7 more
2022Advances in Therapy4 citations Open access
Semantic Scholar
A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)
T. Facon, J. San-Miguel, S. Usmani, M. Dimopoulos +10 more
2019Blood4 citations Open access
Semantic Scholar
Survival of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients Receiving Stem Cell Transplantation (SCT)
R. Nath, V. Reddy, A. Kapur, Samron Gebregergish +4 more
2019Biology of Blood and Marrow Transplantation4 citations Open access
Semantic Scholar
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity
B. Heeg, A. Verhoek, G. Tremblay, Ofir Harari +4 more
2023Journal of Comparative Effectiveness Research3 citations Open access
Semantic Scholar
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
B. Muresan, C. Mamolo, J. Cappelleri, R. Mokgokong +3 more
2021Future Oncology3 citations Open access
Semantic Scholar
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
P. Moreau, C. Hulin, S. Zweegman, M. Hashim +9 more
2020eJHaem3 citations Open access
Semantic Scholar
HTA40 Living Network Meta-Analysis for up-to-Date Comparative Effectiveness: A Case Study in Metastatic Castration Resistant Prostate Cancer (MCRPC)
O. Egunsola, A. Verhoek, J. Liu, K. Thorlund +3 more
2023Value in Health2 citations
Semantic Scholar
HTA35 Should Health Technology Assessment (HTA) Bodies Utilize Living HTA Tools? Validation of LiveSLR® and LiveNMA™ Tools Using ICER’S Class Review in Relapsed Refractory Multiple Myeloma (RRMM)
J. Liu, A. Verhoek, K. Thorlund, B. Heeg +2 more
2022Value in Health2 citations Open access
Semantic Scholar
RW1 Bridging The Gap Between Clinical Trials And Real World Data: Evidence On Replicability Of Efficacy Results Using German Claims Data
M. Ghiani, U. Maywald, T. Wilke, B. Heeg
20202 citations Open access
Semantic Scholar
Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
P. Wigfield, U. Sbarigia, M. Hashim, T. Vincken +1 more
2019PharmacoEconomics - Open2 citations Open access
Semantic Scholar
Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States
H. Pham, S. Milev, Shu-Jun Li, D. Zou +3 more
2019Blood2 citations Open access
Semantic Scholar
Alone, together: On the benefits of Bayesian borrowing in a meta‐analytic setting
Ofir Harari, Mohsen Soltanifar, A. Verhoek, B. Heeg
2023Pharmaceutical statistics1 citations
Semantic Scholar
POSA303 Influence of Treatment Effect on Parameters in Fractional Polynomials for Network Meta-Analyses
D. Freigofaite, A. Verhoek, B. Heeg
2022Value in Health1 citations Open access
Semantic Scholar
MSR134 Optimizing Fractional Polynomials by Using Variable Powers
A. Verhoek, M. Ouwens, B. Heeg
2022Value in Health1 citations Open access
Semantic Scholar
MSR64 Utility Analysis Methods: Can One Method Fit It All or Is a Case-By-Case Approach Required?
A. Kaproulia, B. Humphries, G. Tremblay, B. Heeg +1 more
2022Value in Health1 citations Open access
Semantic Scholar
158P Prevalence and clinical outcomes of MET exon 14 (METex14) skipping in patients with advanced NSCLC: A systematic literature review
A. Cortot, J. Mazières, A. Gezin, A. García +3 more
20211 citations Open access
Semantic Scholar
Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Jian-Ming He, Heather Berringer, B. Heeg, T. Kampfenkel +6 more
2021Blood1 citations Open access
Semantic Scholar
1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial
P. Cheema, B. Heeg, M. Dyer, Y.-L. Wu +9 more
2021Annals of Oncology1 citations Open access
Semantic Scholar
159P Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: A systematic literature review
J. Mazières, A. Cortot, A. Gezin, A. García +3 more
20211 citations Open access
Semantic Scholar
PCN13 Comparing Trial Efficacy And Real-World Effectiveness: A Retrospective Study Of Abiraterone In Metastatic Castration Resistant Prostate Cancer Using German claims
M. Ghiani, U. Maywald, T. Wilke, B. Heeg
20201 citations Open access
Semantic Scholar
Impact of Tafamidis on Life Expectancy and Quality of Life of Transthyretin Amyloid Cardiomyopathy Patients
D. Tran, Benjamin Li, B. Heeg, Rahul Bambri +3 more
20201 citations
Semantic Scholar
PCV57 A Systematic Literature Review of Cost-Utility Analyses of PCSK9 Inhibitors
G. Villa, M. Postma, B. Heeg, F. Kroi +6 more
20201 citations Open access
Semantic Scholar
PCN62 COMPARISON OF NETWORK META-ANALYSES USING STANDARD, MIXTURE CURE AND SPLINE MODELS
M. Kulakova, B. Heeg, D. Ouwens, I. van Oostrum +1 more
2019Value in Health1 citations Open access
Semantic Scholar
PCN430 USING BAYESIAN METHODOLOGIES TO INFORM IMMATURE SURVIVAL EXTRAPOLATIONS BASED ON RWD AND EXPERT ELICITATION IN NON-SMALL CELL LUNG CANCER (NSCLC)
H. El Alili, A. Gezin, M. Postma, D. Ouwens +1 more
2019Value in Health1 citations Open access
Semantic Scholar
PCN441 NEW METHODOLOGY IN NETWORK META-ANALYSIS USING MIXTURE CURE MODELS
I. van Oostrum, M. Ouwens, H. Pham, E. Buskens +2 more
2019Value in Health1 citations Open access
Semantic Scholar
PS1395 COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE
T. Facon, J. San-Miguel, Saad Z. Usmani, M. Dimopoulos +10 more
2019HemaSphere1 citations Open access
Semantic Scholar
MSR83 Predicting Pseudo Individual Patient-Level Data with Covariates
A. Verhoek, H. Moradian, E. Essink, B. Heeg
2023Value in Health0 citations
Semantic Scholar
MSR18 Evaluating the Impact of Random Forest (RF) on Matching Adjusted Indirect Comparisons (MAICS) of Treatments between Trials: A Simulation Study
H. Moradian, B. Heeg, G. Tremblay
2023Value in Health0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Verhoek×12
Invite
A. Verhoek — researcher profile on SciRah
A. Lam×9
Invite
A. Lam — researcher profile on SciRah
M. Hashim×9
Invite
M. Hashim — researcher profile on SciRah
J. Cappelleri×9
Invite
J. Cappelleri — researcher profile on SciRah

×8

Invite

Jian-Ming He — researcher profile on SciRah

Invite

M. Postma — researcher profile on SciRah

M. Dimopoulos×6

Invite

M. Dimopoulos — researcher profile on SciRah

I. van Oostrum×6

Invite

I. van Oostrum — researcher profile on SciRah

Invite

B. Muresan — researcher profile on SciRah

Invite

C. Mamolo — researcher profile on SciRah

Invite

A. Gezin — researcher profile on SciRah

Invite

M. Mateos — researcher profile on SciRah